Allele-Selective Suppression of Mutant Huntingtin in Primary Human Blood Cells.

Citation data:

Scientific reports, ISSN: 2045-2322, Vol: 7, Issue: 1, Page: 46740

Publication Year:
2017
Usage 16
Downloads 9
Abstract Views 7
Captures 2
Readers 2
Social Media 24
Tweets 24
Citations 5
Citation Indexes 5
Repository URL:
https://escholarship.umassmed.edu/oapubs/3135
PMID:
28436437
DOI:
10.1038/srep46740
Author(s):
Miller, James R. C.; Pfister, Edith L.; Liu, Wanzhao; Andre, Ralph; Trager, Ulrike; Kennington, Lori A.; Lo, Kimberly; Dijkstra, Sipke; Macdonald, Douglas; Ostroff, Gary R.; Aronin, Neil; Tabrizi, Sarah J. Show More Hide
Publisher(s):
Springer Nature
Tags:
Multidisciplinary; Diseases of the nervous system; Huntington's disease; Innate immune cells; Cell Biology; Immunity; Immunoprophylaxis and Therapy; Nervous System Diseases
Most Recent Tweet View All Tweets
article description
Post-transcriptional gene silencing is a promising therapy for the monogenic, autosomal dominant, Huntington's disease (HD). However, wild-type huntingtin (HTT) has important cellular functions, so the ideal strategy would selectively lower mutant HTT while sparing wild-type. HD patients were genotyped for heterozygosity at three SNP sites, before phasing each SNP allele to wild-type or mutant HTT. Primary ex vivo myeloid cells were isolated from heterozygous patients and transfected with SNP-targeted siRNA, using glucan particles taken up by phagocytosis. Highly selective mRNA knockdown was achieved when targeting each allele of rs362331 in exon 50 of the HTT transcript; this selectivity was also present on protein studies. However, similar selectivity was not observed when targeting rs362273 or rs362307. Furthermore, HD myeloid cells are hyper-reactive compared to control. Allele-selective suppression of either wild-type or mutant HTT produced a significant, equivalent reduction in the cytokine response of HD myeloid cells to LPS, suggesting that wild-type HTT has a novel immune function. We demonstrate a sequential therapeutic process comprising genotyping and mutant HTT-linkage of SNPs, followed by personalised allele-selective suppression in a small patient cohort. We further show that allele-selectivity in ex vivo patient cells is highly SNP-dependent, with implications for clinical trial target selection.